RT Journal Article SR Electronic T1 Detection of Somatic Copy Number Deletion of CDKN2A Gene for Clinical Practices Based on Discovery of A Base-Resolution Common Deletion Region JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2021.09.16.21263412 DO 10.1101/2021.09.16.21263412 A1 Tian, Yuan A1 Xing, Rui A1 Zhou, Jing A1 Qiao, Juanli A1 Liu, Zhaojun A1 Gu, Liankun A1 Zhang, Baozhen A1 Ji, Jiafu A1 Lu, Youyong A1 Deng, Dajun YR 2021 UL http://medrxiv.org/content/early/2021/10/17/2021.09.16.21263412.abstract AB CDKN2A is most frequently inactivated by somatic copy number deletion (SCND) in human cancers. An accurate method to detect CDKN2A SCND is absent. We extracted interstial base-resolution deletion/fusion coordinates for CDKN2A from published articles and our whole genome sequencing (WGS) datasets, and characterized a 5.1-kb common deletion region (CDR) from the CDKN2A/P16INK4A promoter to intron-2 in 90% (83/92) of cancer cell lines and 100% (18/18) of gastric carcinoma (GC) samples by WGS. Then, a highly reproducible and quantitative assay (P16-Light) targeted to the CDR was setup with a detection limit of 20%. P16-Light was further compared with WGS (gold standard) and loss of heterozygosity (LOH) assay by denaturing high performance liquid chromatography. The positive rate of CDKN2A SCND by P16-Light was more than two times of that by WGS in GCs from a patients cohort (n=156; 25.6% vs. 10.9%), and was significantly correlated with each other (p<0.028). While CDKN2A SCND was significantly associated with GC distant metastasis (p=0.023), such association was not observed for CDKN2A LOH (p=0.213). In conclusion, based on our finding that there is a 5.1-kb CDR within CDKN2A gene, a vary convenient P16-Light assay was setup to detect CDKN2A SCND for clinical applications.Key pointsWe characterized a base resolution common deletion region (CDR) within CDKN2A in human cancers;A novel multiplex PCR method was developed to detect somatic copy number deletion of CDKN2A;The method is very convenient for clinical applications with a high reproducibility and sensitivity.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the Beijing Natural Science Foundation (grant number 7181002 to D.J.D.); Capital's Funds for Health Improvement and Research (grant number 2018-1-1021 to D.J.D.).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Institution Review Board of Peking University Cancer Hospital & Institute approved this study and was carried out in accordance with the principles outlined in the Declaration of Helsinki. Informed consent was obtained from each patient prior to their inclusion in the study.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesDetailed information on the base-resolution interstitial common deletion region in CDKN2A gene in 110 cancer samples was listed in Supplemental Table S1.